Fresh off a Digital Heath Hub award at the HLTH annual conference in Las Vegas in October, AI dermatology company Skin Analytics is aiming to build on its position as the only holder of a class II medical device in the UK to rebuild patient pathways in the country and improve outcomes.With the NHS hampered by a shortage of dermatologists, only 35% of NHS trusts are currently seeing patients within 14 days.

AI皮肤病公司Skin Analytics于10月在拉斯维加斯举行的HLTH年会上颁发数字健康中心奖，旨在建立其作为英国二级医疗器械唯一持有者的地位，以重建患者通路。国家并改善成果。由于NHS受到皮肤科医生短缺的阻碍，目前只有35%的NHS信托在14天内看到患者。

Skin Analytics’ AI medical device DERM has demonstrated its potential to reduce waiting times and improve patient outcomes. “We’ve built AI as a medical device that is able to look at dermoscopic images of skin lesions and identify malignant, pre-malignant and benign lesions,” says Skin Analytics CEO and founder Neil Daly in an interview with Digital Health News.

皮肤分析的AI医疗设备DERM已经证明了其减少等待时间和改善患者预后的潜力。skin Analytics首席执行官兼创始人Neil Daly在接受数字健康新闻采访时说：“我们已经将人工智能构建成一种医疗设备，能够查看皮肤病变的皮肤镜图像并识别恶性，恶变前和良性病变。”。

“This is allowing us to work with NHS partners and build patient pathways so that when patients come in, we can more efficiently route them to the right person.” DERM analyses skin lesions to help doctors find cancers at an early stage. In a review of over 10,000 lesions seen in the last year, DERM identified 98.7% of cancers, including melanoma and squamous cell carcinoma, while also identifying over seven out of every 10 benign lesions that do not require specialist input. Using technology to help streamline pathways The company’s technology enables it to route patients to the correct destination, whether that is a specialist dermatology consultation, a GP surgery or discharge.

“这使我们能够与NHS合作伙伴合作并建立患者通路，以便当患者进来时，我们可以更有效地将他们路由到合适的人。”DERM分析皮肤病变，帮助医生在早期发现癌症。在对去年发现的10000多个病变的回顾中，DERM确定了98.7%的癌症，包括黑色素瘤和鳞状细胞癌，同时还确定了每10个不需要专家输入的良性病变中的7个以上。使用技术帮助简化路径公司的技术使其能够将患者路由到正确的目的地，无论是专科皮肤科咨询，全科医生手术还是出院。

In July, the company was awarded funding from the NHS Cancer Programme Innovation open call, with the support of SBRI Healthcare and the NHS Accelerated Access Collaborative, to scale use in the NHS of its DERM technology. At the time, the company said the new funding would support it and NHS services to open three new skin cancer p.

7月，该公司在SBRI医疗保健和NHS加速接入合作的支持下，获得了NHS癌症计划创新开放电话的资助，以在NHS的DERM技术中大规模使用。当时，该公司表示，新资金将支持它和NHS服务部门开设三种新的皮肤癌p。